초록 ▼

The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network.

The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.

대표청구항 ▼

1. A method of treating Parkinson's disease (PD) or a related disorder in a mammalian subject in need thereof, the method comprising simultaneously, separately or sequentially administering to the subject an effective amount of at least two compounds selected from the group consisting of carbetapent

1. A method of treating Parkinson's disease (PD) or a related disorder in a mammalian subject in need thereof, the method comprising simultaneously, separately or sequentially administering to the subject an effective amount of at least two compounds selected from the group consisting of carbetapentane, rilmenidine, buphenine, carvedilol, cimetidine, ciprofibrate, dexbrompheniramine, ifenprodil, metformin, mexiletine, moxonidine, nitrendipine, and triamterene, or salts, prodrugs, derivatives of any chemical purity, or sustained release formulation thereof, wherein the subject has Parkinson's disease or a related disorder and wherein the related disorder is selected from the group consisting of tremor, bradykinesia, rigidity, postural instability, and abnormal gait. 2. The method of claim 1, wherein a) one compound of the at least two compounds is mexiletine. 3. The method of claim 1, wherein said at least two compounds comprise: carbetapentane and rilmenidine,carbetapentane and carvedilol,cimetidine and rilmenidine,rilmenidine and metformin,rilmenidine and nitrendipine, ormetformin and nitrendipine. 4. The method of claim 1, further comprising administering to the subject an additional compound selected from the group consisting of amiloride, amlexanox, bezafibrate, carbamazepine, gabapentin, ibudilast, leflunomide, losartan, methimazole, naproxen, nicardipine, nicergoline, perhexiline, pyrimethamine, sulodexide and telmisartan, or salts or prodrugs or sustained release formulations thereof. 5. The method of claim 1, further comprising administering to the subject an additional compound selected from the group consisting of levodopa, pergolide, cabergoline, lisuride, pramipexole, ropinirole, apomorphine, selegiline, rasagiline, tolcapone, entacapone, clozapine, desipramine, citalopram, nortriptyline, paroxetine, atomoxetine, venlafaxine, amantadine, donepezil, rivastigmine and memantine, or salts or prodrugs or sustained release formulations thereof. 6. The method of claim 1, wherein said at least two compounds comprise: carbetapentane and rilmenidine and levodopa,cimetidine and rilmenidine and levodopa,rilmenidine and metformin and levodopa,rilmenidine and nitrendipine and levodopa, ormetformin and nitrendipine and levodopa. 7. The method of claim 1, wherein said at least two compounds are administered repeatedly to the subject. 8. The method of claim 1, wherein the said subject in need thereof is also treated with deep brain stimulation of the subthalamic nucleus or of the globus pallidus interna. 9. The method of claim 1, wherein one of the at least two compounds is carbetapentane and the other compound of the at least two compounds is selected from the group consisting of rilmenidine, buphenine, carvedilol, cimetidine, ciprofibrate, dexbrompheniramine, ifenprodil, metformin, mexiletine, moxonidine, nitrendipine, and triamterene, or salts, prodrugs, or sustained release formulation thereof. 10. The method of claim 1, wherein said at least two compounds are formulated together. 11. The method of claim 1, wherein said at least two compounds are formulated separately. 12. The method of claim 1, wherein said at least two compounds are selected from the group consisting of carbetapentane, carvedilol, cimetidine, metformin, nitrendipine and rilmenidine, or salts, prodrugs, or sustained release formulations thereof.